1
|
Baena-Caldas GP, Li J, Pedraza L, Ghosh S, Kalmes A, Barone FC, Moreno H, Hernández AI. Neuroprotective effect of the RNS60 in a mouse model of transient focal cerebral ischemia. PLoS One 2024; 19:e0295504. [PMID: 38166102 PMCID: PMC10760892 DOI: 10.1371/journal.pone.0295504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Accepted: 11/22/2023] [Indexed: 01/04/2024] Open
Abstract
BACKGROUND Stroke is a major cause of death, disability, and public health problems. Its intervention is limited to early treatment with thrombolytics and/or endovascular clot removal with mechanical thrombectomy without any available subacute or chronic neuroprotective treatments. RNS60 has reduced neuroinflammation and increased neuronal survival in several animal models of neurodegeneration and trauma. The aim here was to evaluate whether RNS60 protects the brain and cognitive function in a mouse stroke model. METHODS Male C57BL/6J mice were subjected to sham or ischemic stroke surgery using 60-minute transient middle cerebral artery occlusion (tMCAo). In each group, mice received blinded daily administrations of RNS60 or control fluids (PNS60 or normal saline [NS]), beginning 2 hours after surgery over 13 days. Multiple neurobehavioral tests were conducted (Neurological Severity Score [mNSS], Novel Object Recognition [NOR], Active Place Avoidance [APA], and the Conflict Variant of APA [APAc]). On day 14, cortical microvascular perfusion (MVP) was measured, then brains were removed and infarct volume, immunofluorescence of amyloid beta (Aβ), neuronal density, microglial activation, and white matter damage/myelination were measured. SPSS was used for analysis (e.g., ANOVA for parametric data; Kruskal Wallis for non-parametric data; with post-hoc analysis). RESULTS Thirteen days of treatment with RNS60 reduced brain infarction, amyloid pathology, neuronal death, microglial activation, white matter damage, and increased MVP. RNS60 reduced brain pathology and resulted in behavioral improvements in stroke compared to sham surgery mice (increased memory-learning in NOR and APA, improved cognitive flexibility in APAc). CONCLUSION RNS60-treated mice exhibit significant protection of brain tissue and improved neurobehavioral functioning after tMCAo-stroke. Additional work is required to determine mechanisms, time-window of dosing, and multiple dosing volumes durations to support clinical stroke research.
Collapse
Affiliation(s)
- Gloria Patricia Baena-Caldas
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- Department of Pathology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- Health Sciences Division, Department of Morphology, School of Biomedical Sciences, Universidad del Valle, Cali, Colombia
| | - Jie Li
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
| | - Lina Pedraza
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
| | - Supurna Ghosh
- Revalesio Corporation, Tacoma, WA, United States of America
| | - Andreas Kalmes
- Revalesio Corporation, Tacoma, WA, United States of America
| | - Frank C. Barone
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- The Robert F. Furchgott Center for Neural and Behavioral Science, Downstate Medical Center, State University of New York, Brooklyn, NY, United States of America
| | - Herman Moreno
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- The Robert F. Furchgott Center for Neural and Behavioral Science, Downstate Medical Center, State University of New York, Brooklyn, NY, United States of America
| | - A. Iván Hernández
- Department of Pathology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- The Robert F. Furchgott Center for Neural and Behavioral Science, Downstate Medical Center, State University of New York, Brooklyn, NY, United States of America
| |
Collapse
|
2
|
Baena-Caldas GP, Li J, Ghosh S, Kalmes AA, Barone FC, Moreno H, Hernandez AI. Abstract TP219: Rns60 Brain Protection In Mouse Ischemic Stroke Mitigates Plasma Tau And Cortical Microvascular Perfusion. Stroke 2023. [DOI: 10.1161/str.54.suppl_1.tp219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Introduction:
RNS60 is 0.9% saline solution hypothesized to contain oxygen nanobubbles. Recently, we showed that 13 days of RNS60 treatment after transient middle cerebral artery occlusion (tMCAo) preserves recovery of memory and reduces brain infarction, neuronal cell death, microglial activation, amyloid pathology, and white matter damage. Previously, we also demonstrated the relationship between white matter demyelination and circulating tau in tMCAo. Here we report that RNS60 decreases plasma tau and increases cortical microvascular perfusion (MVP).
Methods:
Male C57BL/6J mice, 3-4 months old, were randomly divided into sham surgery or unilateral 60-minute tMCAo. Each group was subdivided into three treatment arms, receiving daily intraperitoneal administration of 0.2 mL of RNS60, pressurized normal saline (PNS60), or normal saline (NS) starting 2 hours after surgery for 13 days. Treatment assignments were blinded throughout the study. To assess circulating tau, plasma was collected before surgery and on day 14 post-surgery (after MVP measurements). Animals were then euthanized to assess infarct volume using TTC staining.
Results:
RNS60 treatment significantly (p<0.05) reduced brain infarction by 90% compared to controls, reduced plasma tau by 74% of controls, and significantly (p<0.05) increased MVP in motor cortex by 38% and by 39% in the parietal cortex.
Conclusion:
RNS60-treated mice exhibit significant brain protection after ischemic stroke and display decreased plasma tau levels and a significant increase in microvascular perfusion. Ongoing studies are investigating whether increased MVP is due to activation of angiogenesis. These data further support the evaluation of RNS60 in clinical stroke trials.
Collapse
Affiliation(s)
| | - Jie Li
- SUNY Downstate Med Cntr, Brooklyn, NY
| | | | | | | | | | | |
Collapse
|
3
|
Whitehead SN, Bruno A, Burns JM, Carmichael ST, Csiszar A, Edwards JD, Elahi FM, Faraco G, Gould DB, Gustafson DR, Hachinski V, Rosenberg G, Sorond FA, Shih AY, Tse KH, Ungvari Z, Wilcock DM, Zuloaga KL, Barone FC. Expanding the horizon of research into the pathogenesis of the white matter diseases: Proceedings of the 2021 Annual Workshop of the Albert Research Institute for White Matter and Cognition. GeroScience 2022; 44:25-37. [PMID: 34606040 PMCID: PMC8488071 DOI: 10.1007/s11357-021-00461-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 09/14/2021] [Indexed: 12/14/2022] Open
Abstract
White matter pathologies are critically involved in the etiology of vascular cognitive impairment-dementia (VCID), Alzheimer's disease (AD), and Alzheimer's disease and related diseases (ADRD), and therefore need to be considered a treatable target ( Roseborough A, Hachinski V, Whitehead S. White matter degeneration - a treatable target? Roseborough et al. JAMA Neurol [Internet]. 2020 Apr 27;77(7):793-4, [1] . To help address this often-missed area of research, several workshops have been sponsored by the Leo and Anne Albert Charitable Trust since 2015, resulting in the incorporation of "The Albert Research Institute for White Matter and Cognition" in 2020. The first annual "Institute" meeting was held virtually on March 3-4, 2021. The Institute provides a forum and workspace for communication and support of the advancement of white matter science and research to better understand the evolution and prevention of dementia. It serves as a platform for young investigator development, to introduce new data and debate biology mechanisms and new ideas, and to encourage and support new research collaborations and directions to clarify how white matter changes, with other genetic and health risk factors, contribute to cognitive impairment. Similar to previous Albert Trust-sponsored workshops (Barone et al. in J Transl Med 14:1-14, [2]; Sorond et al. in GeroScience 42:81-96, [3]), established expert investigators were identified and invited to present. Opportunities to attend and present were also extended by invitation to talented research fellows and younger scientists. Also, updates on institute-funded research collaborations were provided and discussed. The summary that follows is a synopsis of topics and discussion covered in the workshop.
Collapse
Affiliation(s)
- Shawn N Whitehead
- Department of Anatomy and Cell Biology, Western University, London, ON, N6A 3K7, Canada.
| | - Askiel Bruno
- Department of Neurology, Medical College of Georgia at Augusta University, Augusta, GA, 30912, USA
| | - Jeffrey M Burns
- Department of Neurology, University of Kansas Medical Center, Kansas City, KS, USA
| | - S Thomas Carmichael
- Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA
| | - Anna Csiszar
- Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Translational Medicine, Semmelweis University, Budapest, Hungary
| | - Jodi D Edwards
- University of Ottawa Heart Institute, Ottawa, Canada
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, K1G 5Z3, Canada
| | - Fanny M Elahi
- Memory and Aging Center, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, Suite 190, San Francisco, CA, 94158, USA
| | - Giuseppe Faraco
- Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, 10065, USA
| | - Douglas B Gould
- Departments of Ophthalmology and Anatomy, and Institute for Human Genetics, School of Medicine, University of California, San Francisco, 94143, USA
| | - Deborah R Gustafson
- Department of Neurology, Section for NeuroEpidemiology, State University of New York Downstate Health Sciences University, New York, Brooklyn, 11203, USA
| | - Vladimir Hachinski
- Department of Clinical Neurological Sciences, Western University, London, ON, N6A 5C1, Canada
| | - Gary Rosenberg
- UNM Health Sciences Center, University of New Mexico, Albuquerque, NM, 87106, USA
| | | | - Andy Y Shih
- Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute; Department of Pediatrics; Department of Bioengineering, University of Washington, Seattle, WA, USA
| | - Kai Hei Tse
- Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong
| | - Zoltan Ungvari
- Vascular Cognitive Impairment and Neurodegeneration Program, Oklahoma Center for Geroscience and Healthy Brain Aging, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
- International Training Program in Geroscience, Doctoral School of Basic and Translational Medicine/Department of Translational Medicine, Semmelweis University, Budapest, Hungary
| | - Donna M Wilcock
- Sanders-Brown Center on Aging; Department of Neurology, Department of Behavioral Science, University of Kentucky, Lexington, KY, 40536, USA
| | - Kristen L Zuloaga
- Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, NY, 12208, USA
| | - Frank C Barone
- Department of Neurology, SUNY Downstate Health Sciences University, Brooklyn, NY, 11203, USA
| |
Collapse
|
4
|
Baena-Caldas GP, Li J, Pedraza Ortiz LM, Ghosh S, Kalmes A, Barone FC, Moreno H, Hernandez A. Abstract WP257: RNS60 Provides Acute And Chronic Protection Of Brain Cells And Function In A Mouse Stroke Model. Stroke 2022. [DOI: 10.1161/str.53.suppl_1.wp257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
RNS60 is an experimental treatment containing oxygen nanobubbles. RNS60 has previously been shown to reduce neuroinflammation and increase neuronal survival in animal models of multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson’s diseases, and traumatic brain injury. RNS60 is in phase 2 clinical testing as a treatment for ALS and acute ischemic stroke. Since RNS60 is protective in a variety of pathophysiological conditions that activate neurodegeneration, we evaluated whether RNS60 can reduce brain injury and rescue cognitive functions in a mouse model of ischemic stroke.
Methods:
Male C57BL/6J mice (4 months old) were subjected to transient (60 min) occlusion of the middle cerebral artery (tMCAo) followed by reperfusion, or sham surgery. We investigated the effects of post-stroke RNS60 treatment for 3 or 13 days (beginning 1 hour after reperfusion, 0.2 mL administered i.p., 1/day). Two control treatments (normal saline or oxygenated saline without nanobubbles) were used for comparison. Experimenters were blinded to the treatment groups throughout the study. To assess the post-stroke effects of RNS60 treatments, we performed multiple neurobehavioral tests that included modified neurological severity score (mNSS), novel object recognition (NOR), active place avoidance (APA), and the conflict variant of APA. Brains were collected for assessment of infarct volumes or for immunofluorescence measurements of amyloid, neurons, microglia, and axons.
Results:
Three days of treatment with RNS60 reduced brain infarction, edema, sensory-motor, and cognitive deficits. Thirteen days of treatment reduced brain infarction, amyloid pathology, neuronal cell death, microglial activation, and white matter damage. Noteworthy behavioral effects included recovery of memory during NOR and cognitive flexibility in the APA conflict variant.
Conclusion:
RNS60 treated mice exhibit significant acute and chronic protection of brain cells and neurobehavior after experimental stroke. Our data support the evaluation of RNS60 in clinical stroke trials.
Collapse
Affiliation(s)
| | - Jie Li
- SUNY Downstate Med Cntr, Brooklyn, NY
| | | | | | | | | | | | | |
Collapse
|
5
|
Laing KK, Simoes S, Baena-Caldas GP, Lao PJ, Kothiya M, Igwe KC, Chesebro AG, Houck AL, Pedraza L, Hernández AI, Li J, Zimmerman ME, Luchsinger JA, Barone FC, Moreno H, Brickman AM. Cerebrovascular disease promotes tau pathology in Alzheimer's disease. Brain Commun 2020; 2:fcaa132. [PMID: 33215083 PMCID: PMC7660042 DOI: 10.1093/braincomms/fcaa132] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 07/02/2020] [Accepted: 07/07/2020] [Indexed: 01/04/2023] Open
Abstract
Small vessel cerebrovascular disease, visualized as white matter hyperintensities on T2-weighted magnetic resonance imaging, contributes to the clinical presentation of Alzheimer's disease. However, the extent to which cerebrovascular disease represents an independent pathognomonic feature of Alzheimer's disease or directly promotes Alzheimer's pathology is unclear. The purpose of this study was to examine the association between white matter hyperintensities and plasma levels of tau and to determine if white matter hyperintensities and tau levels interact to predict Alzheimer's disease diagnosis. To confirm that cerebrovascular disease promotes tau pathology, we examined tau fluid biomarker concentrations and pathology in a mouse model of ischaemic injury. Three hundred ninety-one participants from the Alzheimer's Disease Neuroimaging Initiative (74.5 ± 7.1 years of age) were included in this cross-sectional analysis. Participants had measurements of plasma total-tau, cerebrospinal fluid beta-amyloid, and white matter hyperintensities, and were diagnosed clinically as Alzheimer's disease (n = 97), mild cognitive impairment (n = 186) or cognitively normal control (n = 108). We tested the relationship between plasma tau concentration and white matter hyperintensity volume across diagnostic groups. We also examined the extent to which white matter hyperintensity volume, plasma tau, amyloid positivity status and the interaction between white matter hyperintensities and plasma tau correctly classifies diagnostic category. Increased white matter hyperintensity volume was associated with higher plasma tau concentration, particularly among those diagnosed clinically with Alzheimer's disease. Presence of brain amyloid and the interaction between plasma tau and white matter hyperintensity volume distinguished Alzheimer's disease and mild cognitive impairment participants from controls with 77.6% and 63.3% accuracy, respectively. In 63 Alzheimer's Disease Neuroimaging Initiative participants who came to autopsy (82.33 ± 7.18 age at death), we found that higher degrees of arteriosclerosis were associated with higher Braak staging, indicating a positive relationship between cerebrovascular disease and neurofibrillary pathology. In a transient middle cerebral artery occlusion mouse model, aged mice that received transient middle cerebral artery occlusion, but not sham surgery, had increased plasma and cerebrospinal fluid tau concentrations, induced myelin loss, and hyperphosphorylated tau pathology in the ipsilateral hippocampus and cerebral hemisphere. These findings demonstrate a relationship between cerebrovascular disease, operationalized as white matter hyperintensities, and tau levels, indexed in the plasma, suggesting that hypoperfusive injury promotes tau pathology. This potential causal association is supported by the demonstration that transient cerebral artery occlusion induces white matter damage, increases biofluidic markers of tau, and promotes cerebral tau hyperphosphorylation in older-adult mice.
Collapse
Affiliation(s)
- Krystal K Laing
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Sabrina Simoes
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Gloria P Baena-Caldas
- Departments of Neurology and Physiology/Pharmacology, SUNY Downstate, Brooklyn, NY, USA
- School of Biomedical Sciences, Health Sciences Division, Universidad del Valle, Cali, Colombia, USA
| | - Patrick J Lao
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Milankumar Kothiya
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Kay C Igwe
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Anthony G Chesebro
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Alexander L Houck
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - Lina Pedraza
- Departments of Neurology and Physiology/Pharmacology, SUNY Downstate, Brooklyn, NY, USA
| | - A Iván Hernández
- Department of Pathology. SUNY Downstate, Brooklyn, NY, USA
- The Robert F. Furchgott Center for Neural and Behavioral Science, Downstate Medical Center, State University of New York, Brooklyn, NY, USA
| | - Jie Li
- Departments of Neurology and Physiology/Pharmacology, SUNY Downstate, Brooklyn, NY, USA
| | | | - José A Luchsinger
- Department of Medicine, College of Physicians and Surgeons, Department of Epidemiology, Joseph P. Mailman School of Public Health, Columbia University, New York, NY, USA
| | - Frank C Barone
- Departments of Neurology and Physiology/Pharmacology, SUNY Downstate, Brooklyn, NY, USA
- The Robert F. Furchgott Center for Neural and Behavioral Science, Downstate Medical Center, State University of New York, Brooklyn, NY, USA
| | - Herman Moreno
- Departments of Neurology and Physiology/Pharmacology, SUNY Downstate, Brooklyn, NY, USA
- The Robert F. Furchgott Center for Neural and Behavioral Science, Downstate Medical Center, State University of New York, Brooklyn, NY, USA
| | - Adam M Brickman
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, G.H. Sergievsky Center, and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | | |
Collapse
|
6
|
Gerstenhaber JA, Marcinkiewicz C, Barone FC, Sternberg M, D'Andrea MR, Lelkes PI, Feuerstein GZ. Biocompatibility studies of fluorescent diamond particles-(NV)~800nm (part V): in vitro kinetics and in vivo localization in rat liver following long-term exposure. Int J Nanomedicine 2019; 14:6451-6464. [PMID: 31496697 PMCID: PMC6697667 DOI: 10.2147/ijn.s209663] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 07/09/2019] [Indexed: 12/15/2022] Open
Abstract
Background We recently reported on long-term comprehensive biocompatibility and biodistribution study of fluorescent nanodiamond particles (NV)-Z-average 800nm (FNDP-(NV)) in rats. FNDP-(NV) primary deposition was found in the liver, yet liver function tests remained normal. Purpose The present study aimed to gain preliminary insights on discrete localization of FNDP-(NV) in liver cells of the hepatic lobule unit and venous micro-vasculature. Kinetics of FDNP-(NV) uptake into liver cells surrogates in culture was conducted along with cell cytokinesis as markers of cells' viability. Methods Preserved liver specimens from a pilot consisting of two animals which were stained for cytoskeletal elements (fluorescein-isothiocyanate-phalloidin) were examined for distribution of FNDP-(NV) by fluorescent microscopy (FM) and Confocal-FM (CFM) using near infra-red fluorescence (NIR). Hepatocellular carcinoma cells (HepG-2) and human umbilical vein endothelial cells (HUVEC) were cultured with FNDP-(NV) and assayed for particle uptake and location using spectrophotometric technology and microscopy. Results HepG-2 and HUVEC displayed rapid (<30 mins) onset and concentration-dependent FNDP-(NV) internalization and formation of peri-nuclear corona. FM/CFM of liver sections revealed FNDP-(NV) presence throughout the hepatic lobules structures marked by spatial distribution, venous microvascular spaces and parenchyma and non-parenchyma cells. Conclusion The robust presence of FNDP-(NV) throughout the hepatic lobules including those internalized within parenchyma cells and agglomerates in the liver venous micro-circulation were not associated with macro or micro histopathological signs nor vascular lesions. Cells cultures indicated normal cytokinesis in cells containing FNDP-(NV) agglomerates. Liver parenchyma cells and the liver microcirculation remain agnostic to presence of FNDP-(NV) in the sinusoids or internalized in the hepatic cells.
Collapse
Affiliation(s)
- Jonathan A Gerstenhaber
- Department of Bioengineering, College of Engineering, Temple University, Philadelphia, PA, USA
| | - Cezary Marcinkiewicz
- Department of Bioengineering, College of Engineering, Temple University, Philadelphia, PA, USA.,Debina Diagnostic Inc ., Newtown Square, PA, USA
| | - Frank C Barone
- SUNY Downstate Medical Center, Department of Neurology, Brooklyn, NY, USA
| | | | | | - Peter I Lelkes
- Department of Bioengineering, College of Engineering, Temple University, Philadelphia, PA, USA
| | | |
Collapse
|
7
|
Barone FC, Marcinkiewicz C, Li J, Feng Y, Sternberg M, Lelkes PI, Rosenbaum-Halevi D, Gerstenhaber JA, Feuerstein GZ. Long-term biocompatibility of fluorescent diamonds-(NV)-Z~800 nm in rats: survival, morbidity, histopathology, particle distribution and excretion studies (part IV). Int J Nanomedicine 2019; 14:1163-1175. [PMID: 30863052 PMCID: PMC6391148 DOI: 10.2147/ijn.s189048] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background Thromboembolic events are a major cause of heart attacks and strokes. However, diagnosis of the location of high risk vascular clots is hampered by lack of proper technologies for their detection. We recently reported on bio-engineered fluorescent diamond-(NV)-Z~800nm (FNDP-(NV)) conjugated with bitistatin (Bit) and proven its ability to identify iatrogenic blood clots in the rat carotid artery in vivo by Near Infra-Red (NIR) monitored by In Vivo Imaging System (IVIS). Purpose The objective of the present research was to assess the in vivo biocompatibility of FNDP-(NV)-Z~800nm infused intravenously to rats. Multiple biological variables were assessed along this 12 week study commissioned in anticipation of regulatory requirements for a long-term safety assessment. Methods Rats were infused under anesthesia with aforementioned dose of the FNDP-(NV), while equal number of animals served as control (vehicle treated). Over the 12 week observation period rats were tested for thriving, motor, sensory and cognitive functions. At the termination of study, blood samples were obtained under anesthesia for comprehensive hematology and biochemical assays. Furthermore, 6 whole organs (liver, spleen, brain, heart, lung and kidney) were collected and examined ex vivo for FNDP-NV) via NIR monitored by IVIS and histochemical inspection. Results All animals survived, thrived (no change in body and organ growth). Neuro-behavioral functions remain intact. Hematology and biochemistry (including liver and kidney functions) were normal. Preferential FNDP-(NV) distribution identified the liver as the main long-term repository. Certified pathology reports indicated no outstanding of finding in all organs. Conclusion The present study suggests outstanding biocompatibility of FNDP-(NV)-Z~800nm after long-term exposure in the rat.
Collapse
Affiliation(s)
- Frank C Barone
- SUNY Downstate Medical Center, Department of Neurology, Brooklyn, NY, USA
| | - Cezary Marcinkiewicz
- Debina Diagnostic Inc., Newtown Square, PA, USA, .,Department of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA,
| | - Jie Li
- SUNY Downstate Medical Center, Department of Neurology, Brooklyn, NY, USA
| | - Yi Feng
- WuXi AppTec (Suzhou) Co., Ltd., China
| | | | - Peter I Lelkes
- Department of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA,
| | | | - Jonathan A Gerstenhaber
- Department of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA,
| | | |
Collapse
|
8
|
Barone FC, Marcinkiewicz C, Li J, Sternberg M, Lelkes PI, Dikin DA, Bergold PJ, Gerstenhaber JA, Feuerstein G. Pilot study on biocompatibility of fluorescent nanodiamond-(NV)-Z~800 particles in rats: safety, pharmacokinetics, and bio-distribution (part III). Int J Nanomedicine 2018; 13:5449-5468. [PMID: 30271140 PMCID: PMC6149985 DOI: 10.2147/ijn.s171117] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Introduction We hereby report on studies aimed to characterize safety, pharmacokinetics, and bio-distribution of fluorescent nanodiamond particles (NV)-Z~800 (FNDP-(NV)) administered to rats by intravenous infusion in a single high dose. Methods Broad scale biological variables were monitored following acute (90 minutes) and subacute (5 or 14 days) exposure to FNDP-(NV). Primary endpoints included morbidity and mortality, while secondary endpoints focused on hematology and clinical biochemistry biomarkers. Particle distribution (liver, spleen, lung, heart, and kidney) was assessed by whole organ near infrared imaging using an in vivo imaging system. This was validated by the quantification of particles extracted from the same organs and visualized by fluorescent and scanning electron microscopy. FNDP-(NV)-treated rats showed no change in morbidity or mortality and preserved normal motor and sensory function, as assessed by six different tests. Results Blood cell counts and plasma biochemistry remained normal. The particles were principally distributed in the liver and spleen. The liver particle load accounted for 51%, 24%, and 18% at 90 minutes, 5 days, and 14 days, respectively. A pilot study of particle clearance from blood indicated 50% clearance 33 minutes following the end of particle infusion. Conclusion We concluded that systemic exposure of rats to a single high dose of FDNP-(NV)-Z~800 (60 mg/kg) appeared to be safe and well tolerated over at least 2 weeks. These data suggest that FNDP-(NV) should proceed to preclinical development in the near future.
Collapse
Affiliation(s)
- Frank C Barone
- Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA
| | - Cezary Marcinkiewicz
- Department of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA, .,Debina Diagnostics Inc, Newtown Square, PA, USA,
| | - Jie Li
- Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA
| | | | - Peter I Lelkes
- Department of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA,
| | - Dmitriy A Dikin
- Department of Mechanical Engineering, Temple University, Philadelphia, PA, USA
| | - Peter J Bergold
- Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA
| | - Jonathan A Gerstenhaber
- Department of Bioengineering, Temple University, College of Engineering, Philadelphia, PA, USA,
| | | |
Collapse
|
9
|
Barone FC, Gerstenhaber JA, Marcinkiewicz C, Li J, Lelkes PI, Sternberg M, Feuerstein GZ. Abstract WP56: Imaging Intra-Carotid Thrombosis Using Near InfraRed Fluorescent-NanoDiamond Particles Bio-engineered With the Disintegrin Bitistatin. Stroke 2018. [DOI: 10.1161/str.49.suppl_1.wp56] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Thromboembolism is a major cause of events in carotid artery (CA) disease and predisposes the dissemination of clots to upstream ischemic strokes. Although diagnostic methods are available to define thromboembolic strokes (CT, MRI, etc.), there is no technology to provide ambulatory assessment to ‘content image’ thrombi within the CA bifurcation free of the hospital setting. To address this unmet medical need we bioengineered the joining of the disintegrin bitistatin (Bit) to fluorescent NanoDiamond Particles (F-NDP) in order to bind to and non-invasively image vascular clots. F-NDP-Bit preferentially binds to the human platelet fibrinogen receptor (GPIIB/IIIA). F-NDP-Bit was systematically evaluated for NIR emission capacity in various tissues and demonstrated penetration of NIR fluorescence across distances similar to the distance from the human skin surface to the CA bifurcation.
Methods:
In vitro
studies were conducted to evaluate binding of F-NDP-Bit to purified human GPIIB/IIIA. Also, the ability of the F-NDP-Bit to bind to vascular clots
In Vivo
was investigated in rat FeCl3-induced internal CA coagulation.
Results:
Using the specific GPIIB/IIIA antagonist lotrafiban,
In Vitro
specific and concentration-related F-NDP-Bit binding was demonstrated.
In Vivo
, intravenous administration of F-NDP-Bit during the evolution of FeCl3-induced internal CA thrombosis resulted in the dose-related clot accumulation of F-NDP-Bit that was cross-validated by three independent methods (all measures were significant as described; p < 0.05): (
1
)
In Situ
whole rat imaging via
In Vivo
Imaging System (IVIS: using Ex 54 nm; Em 695-770 nm); (
2
)
Ex Vivo
whole vessel/clot imaging (Scanning Confocal Microscopy), and (
3
) Extract, isolate and quantitate F-NDP-Bit following internal CA clot dissolution (12N HNO3) and direct counting (hemocytometer).
Conclusions:
These data indicate that F-NDP-Bit might address the need for fast, safe and highly affordable ambulatory imaging of vascular clot burden. Functionalization of F-NDP with selective ligands that can be pathognomonic for many disease situations also could facilitate risk assessment, earlier intervention and preventative medicine.
Collapse
Affiliation(s)
- Frank C Barone
- Dept of Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | | | | | - Jie Li
- Dept of Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | | | | | | |
Collapse
|
10
|
Selvan P, Li J, Barone FC. Abstract 33: Intra-arterial Saline Flushing Reduces Infarct Size and Improves Sensorimotor Function in a Rat Model of Transient Middle Cerebral Artery Occlusion. Stroke 2018. [DOI: 10.1161/str.49.suppl_1.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
Mechanical thrombectomy (MT) for large vessel occlusive (LVO) stroke provides an opportunity to deliver targeted intra-arterial (IA) adjunctive therapies (ATs) to the ischemic brain. We developed a model of selective IA catheterization after transient middle cerebral artery occlusion (tMCAO) in rats to investigate targeted adjunctive therapies. Here we report the brain protective effects of targeted IA flushing with normal saline as an adjunctive therapy to LVO revascularization.
Methods:
We incorporated a continuous internal carotid artery (ICA) catheter infusion system after tMCAO in Sprague Dawley rats (300-350g). Two groups were studied (N=6/group): Control (tMCAO with IA catheter only) and Flushing (tMCAO with IA catheter and brief intermittent flushing). The Flushing group received 1 min infusions of normal saline at 2cc/min immediately, 1hr, and 2hrs after reperfusion. Laser Speckle Imaging was used to measure microvascular perfusion at baseline, post-occlusion, post-reperfusion, and 24hrs post-reperfusion. Functional measurements and histological analysis were performed at 24hrs post-reperfusion.
Results:
Incorporating a IA catheter system after tMCAO was safe in rats. Flushing saline into the ICA caused a targeted, significantly increased microvascular perfusion of the ischemic MCA territory (P<0.05). Histological analysis demonstrated a significant (P<0.05) decrease in total and cortical infarct size and cortical and striatal swelling. Functional measurements were also significantly decreased (P<0.05) by intermittent flushing.
Conclusion:
Continuous intra-arterial catheter access can be safely incorporated into a rat model of transient middle cerebral artery occlusion. Here we demonstrate that intermittent targeted flushing of the ischemic brain can be effective as an adjunctive therapy to LVO revascularization. It is now possible and necessary to investigate targeted IA therapeutics after tMCAO in rats.
Collapse
Affiliation(s)
- Prad Selvan
- Neurosciences, Univ of California San Diego, San Diego, CA
| | - Jie Li
- Neurology, SUNY Downstate, Brooklyn, NY
| | | |
Collapse
|
11
|
Gerstenhaber JA, Barone FC, Marcinkiewicz C, Li J, Shiloh AO, Sternberg M, Lelkes PI, Feuerstein G. Vascular thrombus imaging in vivo via near-infrared fluorescent nanodiamond particles bioengineered with the disintegrin bitistatin (Part II). Int J Nanomedicine 2017; 12:8471-8482. [PMID: 29200855 PMCID: PMC5703177 DOI: 10.2147/ijn.s146946] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The aim of this feasibility study was to test the ability of fluorescent nanodiamond particles (F-NDP) covalently conjugated with bitistatin (F-NDP-Bit) to detect vascular blood clots in vivo using extracorporeal near-infrared (NIR) imaging. Specifically, we compared NIR fluorescence properties of F-NDP with N-V (F-NDPNV) and N-V-N color centers and sizes (100–10,000 nm). Optimal NIR fluorescence and tissue penetration across biological tissues (rat skin, porcine axillary veins, and skin) was obtained for F-NDPNV with a mean diameter of 700 nm. Intravital imaging (using in vivo imaging system [IVIS]) in vitro revealed that F-NDPNV-loaded glass capillaries could be detected across 6 mm of rat red-muscle barrier and 12 mm of porcine skin, which equals the average vertical distance of a human carotid artery bifurcation from the surface of the adjacent skin (14 mm). In vivo, feasibility was demonstrated in a rat model of occlusive blood clots generated using FeCl3 in the carotid artery bifurcation. Following systemic infusions of F-NDPNV-Bit (3 or 15 mg/kg) via the external carotid artery or femoral vein (N=3), presence of the particles in the thrombi was confirmed both in situ via IVIS, and ex vivo via confocal imaging. The presence of F-NDPNV in the vascular clots was further confirmed by direct counting of fluorescent particles extracted from clots following tissue solubilization. Our data suggest that F-NDPNV-Bit associate with vascular blood clots, presumably by binding of F-NDPNV-Bit to activated platelets within the blood clot. We posit that F-NDPNV-Bit could serve as a noninvasive platform for identification of vascular thrombi using NIR energy monitored by an extracorporeal device.
Collapse
Affiliation(s)
| | - Frank C Barone
- Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, NY
| | - Cezary Marcinkiewicz
- Department of Bioengineering, College of Engineering, Temple University, Philadelphia, PA.,Debina Diagnostic Inc., Newtown Square
| | - Jie Li
- Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, NY
| | | | | | - Peter I Lelkes
- Department of Bioengineering, College of Engineering, Temple University, Philadelphia, PA
| | - Giora Feuerstein
- Department of Bioengineering, College of Engineering, Temple University, Philadelphia, PA.,Debina Diagnostic Inc., Newtown Square
| |
Collapse
|
12
|
Zhou J, Li J, Rosenbaum DM, Zhuang J, Poon C, Qin P, Rivera K, Lepore J, Willette RN, Hu E, Barone FC. The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits. PLoS One 2017; 12:e0184049. [PMID: 28880966 PMCID: PMC5589177 DOI: 10.1371/journal.pone.0184049] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 08/17/2017] [Indexed: 12/20/2022] Open
Abstract
There is interest in pharmacologic preconditioning for end-organ protection by targeting the HIF system. This can be accomplished by inhibition of prolyl 4-hydroxylase (PHD). GSK360A is an orally active PHD inhibitor that has been previously shown to protect the failing heart. We hypothesized that PHD inhibition can also protect the brain from injuries and resulting behavioral deficits that can occur as a result of surgery. Thus, our goal was to investigate the effect of pre-stroke surgery brain protection using a verified GSK360A PHD inhibition paradigm on post-stroke surgery outcomes. Vehicle or an established protective dose (30 mg/kg, p.o.) of GSK360A was administered to male Sprague-Dawley rats. Initially, GSK360A pharmacokinetics and organ distribution were determined, and then PHD-HIF pharmacodynamic markers were measured (i.e., to validate the pharmacological effects of the GSK360A administration regimen). Results obtained using this validated PHD dose-regimen indicated significant improvement by GSK360A (30mg/kg); administered at 18 and 5 hours prior to transient middle cerebral artery occlusion (stroke). GSK360A exposure and plasma, kidney and brain HIF-PHD pharmacodynamics endpoints (e.g., erythropoietin; EPO and Vascular Endothelial Growth Factor; VEGF) were measured. GSK360A provided rapid exposure in plasma (7734 ng/ml), kidney (45–52% of plasma level) and brain (1–4% of plasma level), and increased kidney EPO mRNA (80-fold) and brain VEGF mRNA (2-fold). We also observed that GSK360A increased plasma EPO (300-fold) and VEGF (2-fold). Further assessments indicated that GSK360A reduced post-stroke surgery neurological deficits (47–64%), cognitive dysfunction (60–75%) and brain infarction (30%) 4 weeks later. Thus, PHD inhibition using GSK360A pretreatment produced long-term post-stroke brain protection and improved behavioral functioning. These data support PHD inhibition, specifically by GSK360A, as a potential strategy for pre-surgical use to reduce brain injury and functional decline due to surgery-related cerebral injury.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Behavior, Animal/drug effects
- Brain/drug effects
- Brain/metabolism
- Brain/pathology
- Brain Injuries/blood
- Brain Injuries/drug therapy
- Brain Injuries/etiology
- Brain Injuries/physiopathology
- Cognition Disorders/drug therapy
- Cognition Disorders/etiology
- Erythropoietin/blood
- Erythropoietin/genetics
- Glycine/administration & dosage
- Glycine/analogs & derivatives
- Glycine/pharmacokinetics
- Glycine/pharmacology
- Glycine/therapeutic use
- Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
- Infarction, Middle Cerebral Artery/blood
- Infarction, Middle Cerebral Artery/complications
- Infarction, Middle Cerebral Artery/pathology
- Infarction, Middle Cerebral Artery/physiopathology
- Male
- Motor Activity/drug effects
- Organ Specificity/drug effects
- Prolyl Hydroxylases/metabolism
- Prolyl-Hydroxylase Inhibitors/administration & dosage
- Prolyl-Hydroxylase Inhibitors/pharmacology
- Prolyl-Hydroxylase Inhibitors/therapeutic use
- Quinolones/administration & dosage
- Quinolones/pharmacokinetics
- Quinolones/pharmacology
- Quinolones/therapeutic use
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Rats, Sprague-Dawley
- Sensation/drug effects
- Stroke/blood
- Stroke/complications
- Stroke/physiopathology
- Vascular Endothelial Growth Factor A/blood
- Vascular Endothelial Growth Factor A/genetics
Collapse
Affiliation(s)
- Jin Zhou
- Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
| | - Jie Li
- Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
| | - Daniel M. Rosenbaum
- Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
- Robert F. Furchgott Foundation, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
- Department of Physiology and Pharmacology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
| | - Jian Zhuang
- Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
| | - Carrie Poon
- Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
| | - Pu Qin
- Cardiac Biology, Heart Failure Discovery Performance Unit, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, United States of America
| | - Katrina Rivera
- Cardiac Biology, Heart Failure Discovery Performance Unit, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, United States of America
| | - John Lepore
- Cardiac Biology, Heart Failure Discovery Performance Unit, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, United States of America
| | - Robert N. Willette
- Cardiac Biology, Heart Failure Discovery Performance Unit, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, United States of America
| | - Erding Hu
- Cardiac Biology, Heart Failure Discovery Performance Unit, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, United States of America
| | - Frank C. Barone
- Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
- Robert F. Furchgott Foundation, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
- Department of Physiology and Pharmacology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America
- * E-mail:
| |
Collapse
|
13
|
Nath M, Wagshul ME, Ferbinteanu J, Rosenbaum DM, Selvan P, Anyanwu C, Li J, Barone FC. Abstract TMP97: Demyelination, Cognition and Imaging in a Translational Model of Rat Vascular Cognitive Impairment. Stroke 2017. [DOI: 10.1161/str.48.suppl_1.tmp97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Small vessel disease and/or atherosclerosis produce microvascular and parenchymal inflammation in white matter and results in vascular cognitive impairment (VCI). We have performed bilateral carotid artery stenosis in hypertensive rats (SHR) to better understand disease pathology, targets for intervention and markers.
Hypothesis:
Complex cognitive deficits and diffuse fiber tract changes relevant to human VCI can be quantified and validated for future use.
Methodology:
We performed a series of behavioral assays to test declarative memory and executive functioning in stenosis compared to sham surgery SHR. Behavioral assays included T-maze decision making and alternation, novel object recognition (NOR) and active place avoidance (APA). MRI (DTI, DWI, Arterial Spin Labeling; ASL) and FDG-PET imaging was done in Corpus Callosum (CC). Histology-immunohistochemistry included measurements of microglia (Iba-1), astrocytes (GFAP) and Luxol fast blue (for myelin) in CC.
Results:
Stenosis resulted in consistent executive function decision making (T-maze) deficits (p<0.05) and impaired complex cognitive performance (APA). No significant differences occurred between sham and stenosis animals in NOR and T-maze alternation. DTI analysis indicated significant (p<0.05) changes in the CC of stenosis compared to sham SHR including: (1) decreased fractional anisotropy, (2) increased radial diffusivity, and (3) unchanged axial diffusivity. MRI ASL revealed significant (p<0.05) decreases in white matter perfusion. No significant changes were seen in FDG-PET. In summary, stenosis animals exhibited increased white matter glial cell inflammation related to demyelination and lost cognition. The inflammatory microglia phenotype was verified using TNFα plus Iba-1 double staining. CC changes were significantly (p<0.05) greater in the anterior, periventricular forebrain.
Conclusion:
We have successfully modeled the behavioral, imaging and histologic profile of human VCI in the rat. Currently pre/mature oligodendrocyte changes are being evaluated. This approach provides future opportunities to localize forebrain white matter changes using MR imaging parameters as markers for monitoring VCI demyelination/pathology and intervention.
Collapse
Affiliation(s)
- Manan Nath
- Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | - Mark E Wagshul
- Dept of Radiology, Dept of Physiology and Biophysics, Albert Einstein College of Medicine, Bronx, NY
| | | | | | | | | | - Jie Li
- Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | | |
Collapse
|
14
|
Barone FC, Gustafson D, Crystal HA, Moreno H, Adamski MG, Arai K, Baird AE, Balucani C, Brickman AM, Cechetto D, Gorelick P, Biessels GJ, Kiliaan A, Launer L, Schneider J, Sorond FA, Whitmer R, Wright C, Zhang ZG. First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementia. J Transl Med 2016; 14:50. [PMID: 26873444 PMCID: PMC4752794 DOI: 10.1186/s12967-016-0806-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2015] [Accepted: 01/22/2016] [Indexed: 01/12/2023] Open
Abstract
As the human population continues to age, an increasing number of people will exhibit significant deficits in cognitive function and dementia. It is now recognized that cerebrovascular, metabolic and neurodegenerative diseases all play major roles in the evolution of cognitive impairment and dementia. Thus with our more recent recognition of these relationships and our need to understand and more positively impact on this world health problem, “The Leo and Anne Albert Charitable Trust” (Gene Pranzo, Trustee with significant support from Susan Brogan, Meeting Planner) provided generous support for this inaugural international workshop that was held from April 13–16, 2015 at the beautiful Ritz Carlton Golf Resort in North Naples, Florida. Researchers from SUNY Downstate Medical Center, Brooklyn, NY organized the event by selecting the present group of translationally inclined preclinical, clinical and population scientists focused on cerebrovascular disease (CVD) risk and its progression to vascular cognitive impairment (VCI) and dementia. Participants at the workshop addressed important issues related to aging, cognition and dementia by: (1) sharing new data, information and perspectives that intersect vascular, metabolic and neurodegenerative diseases, (2) discussing gaps in translating population risk, clinical and preclinical information to the progression of cognitive loss, and (3) debating new approaches and methods to fill these gaps that can translate into future therapeutic interventions. Participants agreed on topics for group discussion prior to the meeting and focused on specific translational goals that included promoting better understanding of dementia mechanisms, the identification of potential therapeutic targets for intervention, and discussed/debated the potential utility of diagnostic/prognostic markers. Below summarizes the new data-presentations, concepts, novel directions and specific discussion topics addressed by this international translational team at our “First Leo and Anne Albert Charitable Trust ‘Think Tank’ VCI workshop”.
Collapse
Affiliation(s)
- Frank C Barone
- Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA. .,Physiology and Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
| | - Deborah Gustafson
- Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA. .,Section Neuroepidemiology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
| | - Howard A Crystal
- Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA. .,Pathology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
| | - Herman Moreno
- Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA. .,Physiology and Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
| | - Mateusz G Adamski
- Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Krakow, Poland.
| | - Ken Arai
- Neuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, CharlesTown, Boston, MA, USA.
| | - Alison E Baird
- Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA. .,Physiology and Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY, USA.
| | | | - Adam M Brickman
- Taub Institute for Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, NY, USA.
| | - David Cechetto
- Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
| | - Philip Gorelick
- Translational Science and Molecular Medicine, Michigan State University College of Human Medicine, Mercy Health Hauenstein Neurosciences, Grand Rapids, MI, USA.
| | - Geert Jan Biessels
- Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
| | - Amanda Kiliaan
- Department of Anatomy, Preclinical Imaging Center, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
| | - Lenore Launer
- Neuroepidemiology Section, Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
| | - Julie Schneider
- Pathology (Neuropathology) and Neurological Sciences, Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
| | - Farzaneh A Sorond
- Department of Neurology, Stroke Division, Brigham and Women's Hospital, Boston, MA, USA.
| | - Rachel Whitmer
- Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
| | - Clinton Wright
- McKnight Brain Institute, Division of Cognitive Disorders, Neurology, Public Health Sciences and Neuroscience, University of Miami, Miami, FL, USA.
| | | |
Collapse
|
15
|
Abstract
This review serves to link the role of the immune system in the neuropathology of acute ischemic stroke, traumatic brain injury and neurodegenerative disease. The blood–brain barrier delineates the CNS from the peripheral immune system. However, the blood–cerebrospinal fluid barrier acts as a gate between the periphery and the brain, permitting immune activity crosstalk and modulation. In acute ischemic stroke, traumatic brain injury and other neurodegenerative diseases, the blood–brain barrier is compromised and an influx of inflammatory cells and plasma proteins occurs, resulting in edema, demyelination, cell dysfunction and death, and neurobehavioral changes. The role of the complement system, key cytokines, microglia and other neuroglia in brain degenerative pathology will be discussed.
Collapse
Affiliation(s)
- Rachelle Dugue
- Departments of Neurology & Physiology & Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
| | - Frank C Barone
- Departments of Neurology & Physiology & Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
| |
Collapse
|
16
|
|
17
|
Rosenbaum DM, Zhou J, Zhang H, Li J, Zhuang J, Poon C, Poon C, Barone FC. Abstract T P205: Thrombopoietin Reduces Brain Injury and Cognitive Impairment in Rodent Cerebrovascular Disease Models. Stroke 2014. [DOI: 10.1161/str.45.suppl_1.tp205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objectives:
Thrombopoietin (TPO) reduces brain injury and sensory-motor deficits following stroke in the rat. TPO brain protection is mediated by vascular protection. TPO reduces stroke-induced inflammatory cytokines, matrix metalloproteinase’s and blood brain barrier injury. Here we demonstrate that TPO protects the brain and reduces vascular cognitive impairment in: [1] rat embolic stroke (+/- tissue plasminogen activator; tPA), [2] mouse suture-focal stroke, and [3] mouse chronic carotid stenosis-induced forebrain hypoperfusion.
Methods:
Rats (Wistar) underwent embolic middle cerebral artery occlusion (MCAO). Vehicle, tPA (10 mg/kg, iv), TPO (0.1 μg/kg, iv) or TPO plus tPA were administered 2 hours post-stroke. Mice (C57Bl/6) underwent suture-MCAO or carotid artery stenosis-induced forebrain hypoperfusion and then received Vehicle or TPO (0.3 or 0.1 μg/kg, iv) at 1 hr or 1 day after surgery. Neurological deficits, complex learning and hemispheric infarct size were measured for 1-21 days post-surgery.
Results:
In rat embolic stroke, tPA or TPO plus tPA improved stroke-induced neurological deficits significantly. Significant post-stroke-induced deficits in APA cognitive performance were improved 87.2±16.4% by TPO or 69.4±9.7% by TPO plus tPA, but not by tPA alone. In mouse suture-focal stroke, brain infarcts were reduced by 64.5±7.7% and neurological deficits were reduced by 90.3±6.4%. In mouse carotid artery stenosis-induced forebrain hypoperfusion a single administration of TPO 1 day after surgery improved APA performance 84.8+3.1% 3 weeks later (all p<0.01).
Conclusions:
We have demonstrated TPO long-term protection and safety with and without tPA. TPO exhibits protection in mouse suture-focal and in mouse forebrain hypoperfusion-induced complex learning deficits. These data present multiple model and species work that supports the potential “multiple use” of TPO in the future.
Collapse
Affiliation(s)
| | - Jin Zhou
- Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | - Haiyan Zhang
- Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | - Jie Li
- Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | - Jiang Zhuang
- Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | - Carrie Poon
- Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | - Carrie Poon
- Neurology, SUNY Downstate Med Cntr, Brooklyn, NY
| | | |
Collapse
|
18
|
Zhou J, Zhuang J, Li J, Ooi E, Bloom J, Poon C, Lax D, Rosenbaum DM, Barone FC. Long-term post-stroke changes include myelin loss, specific deficits in sensory and motor behaviors and complex cognitive impairment detected using active place avoidance. PLoS One 2013; 8:e57503. [PMID: 23505432 PMCID: PMC3591420 DOI: 10.1371/journal.pone.0057503] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Accepted: 01/22/2013] [Indexed: 12/14/2022] Open
Abstract
Persistent neurobehavioral deficits and brain changes need validation for brain restoration. Two hours middle cerebral artery occlusion (tMCAO) or sham surgery was performed in male Sprague-Dawley rats. Neurobehavioral and cognitive deficits were measured over 10 weeks included: (1) sensory, motor, beam balance, reflex/abnormal responses, hindlimb placement, forepaw foot fault and cylinder placement tests, and (2) complex active place avoidance learning (APA) and simple passive avoidance retention (PA). Electroretinogram (ERG), hemispheric loss (infarction), hippocampus CA1 neuronal loss and myelin (Luxol Fast Blue) staining in several fiber tracts were also measured. In comparison to Sham surgery, tMCAO surgery produced significant deficits in all behavioral tests except reflex/abnormal responses. Acute, short lived deficits following tMCAO were observed for forelimb foot fault and forelimb cylinder placement. Persistent, sustained deficits for the whole 10 weeks were exhibited for motor (p<0.001), sensory (p<0.001), beam balance performance (p<0.01) and hindlimb placement behavior (p<0.01). tMCAO produced much greater and prolonged cognitive deficits in APA learning (maximum on last trial of 604±83% change, p<0.05) but only a small, comparative effect on PA retention. Hemispheric loss/atrophy was measured 10 weeks after tMCAO and cross-validated by two methods (e.g., almost identical % ischemic hemispheric loss of 33.4±3.5% for H&E and of 34.2±3.5% for TTC staining). No visual dysfunction by ERG and no hippocampus neuronal loss were detected after tMCAO. Fiber tract damage measured by Luxol Fast Blue myelin staining intensity was significant (p<0.01) in the external capsule and striatum but not in corpus callosum and anterior commissure. In summary, persistent neurobehavioral deficits were validated as important endpoints for stroke restorative research in the future. Fiber myelin loss appears to contribute to these long term behavioral dysfunctions and can be important for cognitive behavioral control necessary for complex APA learning.
Collapse
Affiliation(s)
- Jin Zhou
- Department of Neurology, State University of New York Downstate Medical Center, Brooklyn, New York, United States of America.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Bapat M, Musikantow D, Khmara K, Chokshi P, Khanna N, Galligan S, Kamran H, Salciccioli L, Barone FC, Lazar JM. Comparison of passive leg raising and hyperemia on macrovascular and microvascular responses. Microvasc Res 2012; 86:30-3. [PMID: 23261755 DOI: 10.1016/j.mvr.2012.12.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2012] [Accepted: 12/06/2012] [Indexed: 11/19/2022]
Abstract
Passive leg raising is a simple diagnostic maneuver that has been proposed as a measure of arterial vasodilator reserve and possibly endothelial function. While passive leg raising has previously been shown to lower blood pressure, increase flow velocity and cause brachial artery dilation, its effects on microvascular flow has not been well studied. Also, passive leg raising has been directly compared previously to upper arm but never to lower arm occlusion of blood flow induced hyperemia responses. We compared changes in macrovascular indices measured by brachial artery ultrasound and microvascular perfusion measured by Laser Doppler Flowmetry induced by passive leg raising to those provoked by upper arm and lower arm induced hyperemia in healthy subjects. Upper arm induced hyperemia increased mean flow velocity by 398%, induced brachial artery dilatation by 16.3%, and increased microvascular perfusion by 246% (p<.05 for all). Lower arm induced hyperemia increased flow velocity by 227%, induced brachial artery dilatation by 10.8%, and increased microvascular perfusion by 281%. Passive leg raising increased flow velocity by 29% and brachial artery dilatation by 5.6% (p<.05 for all), but did not change microvascular perfusion (-5%, p=ns). In conclusion, passive leg raising increases flow velocity orders of magnitude less than does upper arm or lower arm induced hyperemia. Passive leg raising-induced brachial artery dilatation is less robust than either of these hyperemic techniques. Finally, although upper arm and lower arm hyperemia elicits macrovascular and microvascular responses, passive leg raising elicits only macrovascular responses.
Collapse
Affiliation(s)
- Manasi Bapat
- Division of Cardiovascular Medicine, State University of New York Downstate Medical Center, Brooklyn, NY 11203-2098, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Gevorgyan T, Graber HL, Pfeil DS, Mangla S, Barone FC, Libien J, Charchaflieh J, Kral JG, Barbour RL, Lee DC. Near infrared spectroscopic tomography for cerebral monitoring of stroke and intracranial hemorrhage. J Am Coll Surg 2012. [DOI: 10.1016/j.jamcollsurg.2012.06.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Barone FC, Adamski MG, Baird AE. The 2012 American Heart Association/American Stroke Association International Stroke Conference. Future Neurology 2012. [DOI: 10.2217/fnl.12.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The 2012 International Stroke Conference was held in New Orleans (LA, USA)between the 1st and 3rd of February. The conference maintained a focus on young investigators and career advice, including a session by the NIH/NINDS on how to get funding, with additional special sessions and lunches devoted to stimulating young investigators. Another focus of the meeting was on translational science. The performance of a number of outstanding scientists was recognized. Here we list several highlights from the meeting in more detail.
Collapse
Affiliation(s)
- Frank C Barone
- Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA
| | - Mateusz G Adamski
- Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA
- Neurology, Jagiellonian Medical College, Krakow, Poland
| | - Alison E Baird
- Neurology, SUNY Downstate Medical Center, Brooklyn, NY, USA
| |
Collapse
|
22
|
|
23
|
Barone FC. Post-stroke pharmacological intervention: promoting brain recovery from injury in the future. Neuropharmacology 2010; 59:650-3. [PMID: 20804774 DOI: 10.1016/j.neuropharm.2010.08.016] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2010] [Accepted: 08/19/2010] [Indexed: 11/29/2022]
Affiliation(s)
- Frank C Barone
- SUNY Downstate Medical Center, 450 Clarkson Avenue, Box 1213, Brooklyn, NY 11203, USA.
| |
Collapse
|
24
|
Hansen MK, McVey MJ, White RF, Legos JJ, Brusq JM, Grillot DA, Issandou M, Barone FC. Selective CETP Inhibition and PPARα Agonism Increase HDL Cholesterol and Reduce LDL Cholesterol in Human ApoB100/Human CETP Transgenic Mice. J Cardiovasc Pharmacol Ther 2010; 15:196-202. [DOI: 10.1177/1074248410362891] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cholesteryl ester transfer protein (CETP) plays a key role in high-density lipoprotein (HDL) cholesterol metabolism, but normal mice are deficient in CETP. In this study, transgenic mice expressing both human apolipoprotein B 100 (ApoB-100) and human CETP (hApoB100/hCETP) were used to characterize the effects of CETP inhibition and peroxisome proliferator—activated receptor α (PPARα) agonism on lipid profiles. Torcetrapib (3, 10, and 30 mg/kg), a CETP inhibitor, fenofibrate (30 mg/kg), a weak PPARα agonist, and GW590735 (3 and 10 mg/kg), a potent and selective PPARα agonist were given orally for 14 days to hApoB100/hCETP mice and lipid profiles were assessed. The average percentages of HDL, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) cholesterol fractions in hApoB100/hCETP mice were 34.8%, 61.6%, and 3.6%, respectively, which is similar to those of normolipidemic humans. Both torcetrapib and fenofibrate significantly increased HDL cholesterol and reduced LDL cholesterol, and there was a tendency for torcetrapib to reduce VLDL cholesterol and triglycerides. GW590735 significantly increased HDL cholesterol, decreased LDL and VLDL cholesterol, and significantly reduced triglycerides. Maximal increases in HDL cholesterol were 37%, 53%, and 84% with fenofibrate, torcetrapib, and GW590735, respectively. These results, in mice that exhibit a more human-like lipid profile, demonstrate an improved lipid profile with torcetrapib, fenofibrate, and GW590735, and support the use of selective PPARα agonism for the treatment of lipid disorders. In addition, these data demonstrate the use of hApoB100/hCETP transgenic mice to identify, characterize, and screen compounds that increase HDL cholesterol.
Collapse
Affiliation(s)
| | | | - Ray F. White
- Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA
| | | | - Jean-Marie Brusq
- Center for Cardiovascular Research, GlaxoSmithKline, Les Ulis, France
| | - Didier A. Grillot
- Center for Cardiovascular Research, GlaxoSmithKline, Les Ulis, France
| | - Marc Issandou
- Center for Cardiovascular Research, GlaxoSmithKline, Les Ulis, France
| | - Frank C. Barone
- Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA
| |
Collapse
|
25
|
Chavez JC, Hurko O, Barone FC, Feuerstein GZ. Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke 2009; 40:e558-63. [PMID: 19745180 DOI: 10.1161/strokeaha.109.559914] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE The majority of pharmacological agents for stroke were developed based on the assumption that neurological deficits will be reduced upon the successful interruption of biochemical mechanisms leading to neuronal death. Despite significant evidence of preclinical efficacy, none of these agents succeeded. They either failed to demonstrate efficacy in the clinic or their development was halted for safety, strategic, or commercial reasons. SUMMARY OF REVIEW This "neuroprotection strategy" has focused primarily on targets in the neurotoxic environment that occurs under ischemic conditions. In many cases, these agents were designed to tackle events that are known to start almost immediately after onset of ischemia, which is far before a realistic therapeutic time window opens for most, if not all, patients with stroke. In other instances, they were evaluated beyond a realistic timeframe in which one could expect significant salvageable tissue or penumbra to exist. Surprisingly, most of these agents were not evaluated in conjunction with strategies for improving perfusion to the affected tissue, indicating an overoptimistic assumption that neuroprotection alone could be sufficient to halt injury caused by an abrupt interruption of brain blood flow. CONCLUSIONS We provide a constructive translational medicine perspective about how one could improve the drug development process with the hope that the probability for success can increase in our quest to establish a novel therapy for stroke.
Collapse
Affiliation(s)
- Juan C Chavez
- Department of Translational Medicine, Wyeth Research, Collegeville, PA 19426, USA.
| | | | | | | |
Collapse
|
26
|
Barone FC, Rosenbaum DM, Zhou J, Crystal H. Vascular cognitive impairment: dementia biology and translational animal models. Curr Opin Investig Drugs 2009; 10:624-637. [PMID: 19579168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Relationships between cardiovascular risk and disease, and dementia have been identified, and the term vascular cognitive impairment (VCI) is used to describe individuals with significant cognitive impairments produced by cerebrovascular disease (CVD). VCI is the second most prevalent form of dementia and is composed of a heterogeneous pathology. Risk factors for VCI are similar to those of the most prevalent form of dementia, Alzheimer's disease (AD). In addition, recent data suggest that VCI can contribute significantly to the progression of AD, and AD can contribute to VCI. Translational animal models of VCI are necessary to further understand CVD mechanisms contributing to impaired cognition. This review describes animal models of cerebrovascular insufficiency (ie, chronic hypoperfusion and hypertension) that produce experimental VCI, including their relationships to human VCI and, when appropriate, to AD. The use of these models is expected to help discover biomarkers and disease mechanism-linked targets for diagnostic and therapeutic purposes, thus facilitating early identification and intervention in VCI.
Collapse
Affiliation(s)
- Frank C Barone
- SUNY Downstate Medical Center, School of Medicine, Department of Neurology, 450 Clarkson Avenue, Box 1213, Brooklyn, NY 11225, USA.
| | | | | | | |
Collapse
|
27
|
Barone FC. Ischemic stroke intervention requires mixed cellular protection of the penumbra. Curr Opin Investig Drugs 2009; 10:220-223. [PMID: 19333878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The failure of many acute stroke intervention clinical trials has raised significant concerns regarding neuroprotection alone as a strategy for therapeutic intervention in the treatment of stroke. 'Neuroprotection' strategies typically have focused on neurons and the neurotoxic environment observed under ischemic conditions; however, the complex processes that occur post-stroke require the targeting of multiple factors and cells, including glia, vascular and inflammatory cells, and multiple types of cell death (eg, including the death of axons/white matter). Although the ischemic penumbra (the brain areas bordering the ischemic core) can be salvaged by interventions much later post-stroke than the ischemic core, future interventions need to target the multiple cell types involved in the evolution of the penumbra to infarction (ie, to improve treatment outcome by maintaining the integrity of the brain at risk for injury post-stroke).
Collapse
Affiliation(s)
- Frank C Barone
- Department of Neurology, The State University of New York Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11225, USA.
| |
Collapse
|
28
|
Haskova Z, Hoang B, Luo G, Morgan LA, Billin AN, Barone FC, Shearer BG, Barton ME, Kilgore KS. Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta/delta ligand GW0742. Inflamm Res 2008; 57:314-21. [PMID: 18622687 DOI: 10.1007/s00011-007-7157-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
OBJECTIVE To define the anti-inflammatory effects of PPARbeta/delta activation by use of the selective PPARbeta/delta ligand (GW0742) in a model of lipopolysaccharide (LPS)-induced pulmonary inflammation. METHODS Male BALB/c mice were pretreated for three days with the PPARbeta/delta agonist, GW0742, prior to induction of LPS-mediated pulmonary inflammation. Bronchial alveolar lavage fluid (BALF) was analyzed for inflammatory cell influx and for levels of pro-inflammatory mediators. BALF-derived inflammatory cells were also collected for mRNA analysis. RESULTS Pretreatment with GW0742 resulted in a significant decrease in leukocyte recruitment into the pulmonary space. Protein and mRNA levels of the pro-inflammatory cytokines IL-6, IL-1beta and TNFalpha in BALF were found to be significantly decreased in GW0742-treated animals (30 mg/kg). A significant decrease in granulocyte macrophage-colony stimulating factor (GM-CSF), a major regulator of neutrophil chemotaxis (via its downstream actions on TNFalpha and other cytokines/chemokines), activation and survival, was also noted in the BALF levels of GW0742-treated animals. CONCLUSIONS The present study demonstrates that activation of PPARbeta/delta attenuates the degree of inflammation in a model of LPS-induced pulmonary inflammation and may therefore represent a novel therapeutic approach for the treatment of inflammation-mediated pathologies.
Collapse
Affiliation(s)
- Z Haskova
- Biopharmaceutical Center for Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A. Parsons, Barone FC. SB 234551 selective ETA receptor antagonism: Perfusion/Diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Exp Neurol 2008; 212:53-62. [DOI: 10.1016/j.expneurol.2008.03.011] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Revised: 02/29/2008] [Accepted: 03/03/2008] [Indexed: 10/22/2022]
|
30
|
Barone FC, Barton ME, White RF, Legos JJ, Kikkawa H, Shimamura M, Kuratani K, Kinoshita M. Inhibition of Phosphodiesterase Type 4 Decreases Stress-Induced Defecation in Rats and Mice. Pharmacology 2007; 81:11-7. [PMID: 17726343 DOI: 10.1159/000107662] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2007] [Accepted: 05/02/2007] [Indexed: 12/14/2022]
Abstract
BACKGROUND/AIMS Phosphodiesterase type 4 (PDE4) has been previously shown to regulate colonic contractile activity in vitro. In this study, the effects of PDE4 inhibition were assessed in a model of stress-induced defecation previously demonstrated to be due to increased colonic transit/evacuation. METHODS Rats were individually placed in a mild restraint cage and placed into a 12 degrees C environment (cold-restraint stress) for 60 min. Mice received restraint (only) stress at room temperature for 30 min. Loperamide (positive control compound) or two different PDE4 inhibitors (rolipram and roflumilast) were administered orally at several doses to the rodents 1 h before stress began. Vehicle alone was administered for comparison. The number of fecal pellets expelled during stress (fecal pellet output), total fecal pellet wet weight and total fecal water content were measured. RESULTS Loperamide produced a dose-related decrease (ID(50)s in mg/kg) in fecal pellet output (rat = 7.4, mouse = 0.7) and significantly decreased fecal wet weight (72.9%) and decreased fecal percent water content (9.4%). The two PDE4 inhibitors produced a similar dose-related inhibition of fecal pellet output. Rolipram exhibited ID(50)s in rat and mouse of 14.1 and 27.1, respectively. Rolipram significantly decreased fecal wet weight (58.8%) but increased fecal percent water content (15.0%). For roflumilast, ID(50)s were 24.2 mg/kg and 12.4 in the rat and mouse, respectively. Although roflumilast also significantly (p < 0.05) decreased fecal wet weight (47.2%), it did not significantly increase fecal percent water content. CONCLUSIONS These data indicate that PDE4 inhibition is effective in reducing rodent stress-induced defecation, provides the first functional data on a potential role for PDE4 activity in the colonic evacuation response to stress, and indicates the potential utility of PDE4 inhibitors in functional bowel disease such as irritable bowel syndrome requires further evaluation.
Collapse
Affiliation(s)
- Frank C Barone
- Discovery Research, High Throughput Biology, GlaxoSmithKline, King of Prussia, PA 19406, USA.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Lenhard SC, Strittmatter R, Price WJ, Chandra S, White RF, Barone FC. Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine. Pharmacology 2007; 81:1-10. [PMID: 17726342 DOI: 10.1159/000107661] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2006] [Accepted: 04/09/2007] [Indexed: 11/19/2022]
Abstract
BACKGROUND/AIMS Isradipine, a calcium channel blocker, provides consistent protection of the brain from injury and reduces neurological deficits produced by ischemic stroke in hypertensive rats. In these experiments, isradipine was utilized to cross-validate both the serial MRI measurement of brain infarctions with histology measurements and to validate a series of simple neurological deficit tests in order to establish a more rapid, higher throughput approach to screening compounds for utility in stroke. METHODS Spontaneously hypertensive rats were treated with vehicle, or 2.5 or 5.0 mg/kg isradipine and middle cerebral artery occlusion. T(2)-weighted MRI image analysis was compared to standard triphenyltetrazolium chloride-stained histological image analysis of brain sections to quantify isradipine neuroprotection 1, 3, and 30 days after middle cerebral artery occlusion (MCAO; stroke). In addition, serial evaluation (i.e. 1, 2, 5, 12, 20 and 30 days after MCAO) of four simple neurobehavioral tests were completed for each animal. Tests included assessment of hindlimb and forelimb function, and balance beam and proprioception performance. RESULTS At 1, 3 and 30 days there was a significant positive correlation of the percent hemispheric infarct for T(2)-weighted MRI and histology (p < 0.05). Practically identical isradipine dose-response neuroprotection curves were observed for both measurement procedures. Isradipine produced a dose-related reduction in all neurological deficits scored by the four neurological deficit tests (p < 0.05). In addition, a significant time-related recovery from neurological deficits in vehicle-treated rats was observed (p < 0.05). The four different neurological deficit tests did provide unique time-related profiles of neurological recovery. CONCLUSIONS The present study validates the use of serial MRI in experimental stroke and establishes several simple neurological tests that can be used to measure neurological/behavioral deficits associated with brain injury and brain recovery of function over time. Under these conditions, T(2)-weighted MRI and neurological testing required only about 10 min each per animal, thus providing rapid data collection and analysis and requiring reduced scientific personnel.
Collapse
Affiliation(s)
- Stephen C Lenhard
- Cardiovascular and Urogenital Center of Excellence for Drug Discovery, King of Prussia, PA, USA
| | | | | | | | | | | |
Collapse
|
32
|
Barone FC, Willette RN, Nelson AH, Ohlstein EH, Brooks DP, Coatney RW. Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction. Pharmacology 2007; 80:166-76. [PMID: 17551266 DOI: 10.1159/000103384] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2006] [Accepted: 01/22/2007] [Indexed: 11/19/2022]
Abstract
BACKGROUND/AIMS Histological studies have provided evidence that carvedilol can prevent cardiac hypertrophy in spontaneously hypertensive-stroke prone rats (SP) fed a high-fat and -salt diet. However, the effects of carvedilol on cardiac function have not been studied in these animals. In addition, the ability of carvedilol to reverse established cardiac hypertrophy and dysfunction under these conditions remains to be determined. Here we have evaluated the ability of carvedilol to prevent and reverse cardiac hypertrophy and progressive dysfunction using echocardiography. METHODS Two echocardiology studies were conducted to determine the effects of carvedilol treatment on cardiac hypertrophy and dysfunction. In the first prevention study, four groups of rats were evaluated. SP were fed a high-fat (24.5% in food) and high-salt (1% in water) diet (SFD) without (SP-SFD control group) or with carvedilol (SP-SFD carvedilol group; carvedilol concentration 2,400 parts per million) for 18 weeks. Carvedilol was administered in the food at an optimum concentration (i.e. known to provide clinically relevant blood concentrations and reduce cardiac hypertrophy determined from previous studies). In addition, SP and WKY rats were fed a normal diet (SP normal diet group and WKY normal diet group). These groups are known to not develop the same significant cardiac hypertrophy and dysfunction within this limited time of study, and provided two more normal control groups for comparison. In the second reversal study, one group of SP was fed SFD for 12 weeks (SP-SFD pretreatment period) to induce cardiac hypertrophy. Carvedilol (2,400 parts per million) was then added to the diet for an additional 6 weeks (SP-SFD carvedilol treatment period). RESULTS In the first prevention study, carvedilol prolonged longevity (p < 0.05) and prevented left-ventricular hypertrophy and dysfunction (p < 0.05; SP-SFD control vs. SP-SFD carvedilol group). M-mode-measured and -calculated parameters demonstrated that carvedilol treatment in the SP-SFD carvedilol group prevented increases in left-ventricular wall thickness (p < 0.05) and decreases in diastolic chamber diameter and volume, stroke volume, ejection fraction and cardiac output (all p < 0.05) that occurred in the SP-SFD control group. Further, cardiac measurements in the SP-SFD carvedilol group were normalized to levels similar to those in the SP and WKY normal diet groups. All SFD-fed groups exhibited similar, significantly elevated blood pressure during the study. In the second reversal study, carvedilol treatment for 6 weeks reversed the cardiac hypertrophy and dysfunction that developed in SP-fed SFD for 12 weeks prior to carvedilol intervention. Under these conditions, carvedilol improved/normalized left-ventricular wall thickness, diastolic ventricular-chamber diameter and volume, stroke volume, ejection fraction and cardiac output (all p < 0.05). CONCLUSIONS These data indicate that carvedilol provides protection from and facilitates reversal of progressive cardiac remodeling and dysfunction in this SP-SFD model of cardiac hypertrophy/heart failure. Since these effects occurred in the absence of effects on blood pressure, other known actions of carvedilol, especially its antioxidant activity, for example, may explain this significant cardiac protection. In addition, research using this SP-SFD model of cardiac hypertrophy/end-organ injury appears to translate well to human cardiovascular disease.
Collapse
Affiliation(s)
- Frank C Barone
- High Throughput Biology, Discovery Research, King of Prussia, PA, USA.
| | | | | | | | | | | |
Collapse
|
33
|
Barone FC. Cardiovascular disease strategies--directions after the human genome. Curr Opin Investig Drugs 2006; 7:789-91. [PMID: 17002255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
|
34
|
Barone FC. Emerging therapeutic targets in focal stroke and brain trauma: cytokines and the brain inflammatory response to injury. ACTA ACUST UNITED AC 2005. [DOI: 10.1517/14728222.2.2.17] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
35
|
Abstract
Ischaemic stroke usually results from the obstruction of a major cerebral vessel which leads to a decrease in cerebral blood flow, and a subsequent reduction in ATP. This energy loss leads to impaired cellular function due to reduced ATP-dependent processes and a disruption in ionic gradients across membranes. Under these conditions, there is a significant efflux of K+ from cells producing cellular depolarisation and the movement of extracellular calcium into cells through calcium channels. It is this increase in intracellular calcium that leads to the 'calcium toxicity' that has been associated with cerebral ischaemia. Increased intracellular calcium triggers the break-down of phospholipids, proteins and nucleic acids. This is activated by calcium-dependent phospholipases, proteases and endonucleases, and contributes to structural and functional damage of the cell membrane, which compromises cell function and facilitates cell death. Calcium channel blockers are used routinely to treat cardiovascular disease and hypertension. Although some experimental studies over the last decade suggest efficacy/benefit in the treatment of experimental ischaemic stroke, clinical data do not bear this out. This article discusses the role of voltage-operated calcium channel blockers in stroke, and reviews much of the available experimental and clinical data.
Collapse
Affiliation(s)
- F C Barone
- Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, UW2521, King of Prussia, PA 19406, USA.
| | | | | |
Collapse
|
36
|
Abstract
Almost all injurious stimuli, when applied below the threshold of producing injury, activate endogenous protective mechanisms that significantly decrease the degree of injury after subsequent injurious stimuli. For example, a short duration of ischemia (i.e., ischemic preconditioning [PC]) can provide significant brain protection to subsequent long-duration ischemia (i.e., ischemic tolerance [IT]). PC/IT has recently been shown in human brain, suggesting that learning more about these endogenous neuroprotective mechanisms could help identify new approaches to treat patients with stroke and other central nervous system disorders/injury. This chapter provides a brief overview of PC/IT research, illustrates the types of data that can be generated from in vivo and in vitro models to help us understand gene and protein expression related to induced neuroprotective mechanisms, and emphasizes the importance of future research on this phenomenon to help discover new mechanisms and targets for the medical treatment of brain and other end-organ injuries.
Collapse
Affiliation(s)
- Frank C Barone
- High-Throughput Biology, Discovery Research, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA
| |
Collapse
|
37
|
Read SJ, Barone FC. Introduction to stroke genomics. Methods Mol Med 2004; 104:3-16. [PMID: 15454662 DOI: 10.1385/1-59259-836-6:003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
Translation of the explosion in knowledge of acute ischemic stroke into satisfactory treatment regimens has yet to happen. At present tPA, intra-arterial prourokinase and low-molecular-weight heparin form the vanguard for therapeutic intervention, yet these treatments have a limited therapeutic window. Part of this expansion in understanding has been driven by the contribution of stroke genetics and genomics. However, despite the enormous preclinical and clinical information of receptors, enzymes, second messenger systems, and so forth, that are implicated in stroke pathophysiology, delivery of novel drug treatment has been slow. This introductory chapter discusses the multiple sources of clinical and preclinical genetic information. It will describe the importance of integrating expression information into multiple preclinical models with temporal and spatial roles in lesion pathology and, furthermore developing an understanding of function in the clinic before claiming a role in ischemic stroke. The goal of such a holistic integration of information is to increase the yield from current datasets of gene expression and ultimately to help expand the choice of treatment available to the physician and patient.
Collapse
Affiliation(s)
- Simon J Read
- AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom
| | | |
Collapse
|
38
|
Takahashi K, Ginis I, Nishioka R, Klimanis D, Barone FC, White RF, Chen Y, Hallenbeck JM. Glucosylceramide synthase activity and ceramide levels are modulated during cerebral ischemia after ischemic preconditioning. J Cereb Blood Flow Metab 2004; 24:623-7. [PMID: 15181369 DOI: 10.1097/01.wcb.0000119990.06999.a9] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
After 24-hour middle cerebral artery occlusion (MCAO) in spontaneously hypertensive rats, brain ceramide level increased from baseline reached 595% (ischemic core) and 460% (perifocal/penumbral areas); brain glucosylceramide synthase (GCS) activities in these areas simultaneously decreased by 70% and 50%, respectively. Ten-minute MCAO preconditioning significantly attenuated 24-hour MCAO-induced ceramide accumulation by 40% to 60% in ischemic core and perifocal areas, and GCS activities improved by 60% to 70% in both areas. Thus, potentially toxic levels of brain ceramide induced by MCAO were attenuated to intermediate levels in preconditioned animals; brain GCS activity was relatively preserved. In ischemic tolerance, GCS appears to modulate otherwise high levels of brain ceramide.
Collapse
Affiliation(s)
- Kenzo Takahashi
- Stroke Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Behr TM, Willette RN, Coatney RW, Berova M, Angermann CE, Anderson K, Sackner-Bernstein JD, Barone FC. Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease. J Hypertens 2004; 22:583-92. [PMID: 15076165 DOI: 10.1097/00004872-200403000-00022] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE The purpose of this investigation was to determine whether angiotensin II receptor (AII1R) antagonism interferes with cardiac monocyte chemoattractant protein-1 (MCP-1) expression in hypertrophic cardiomyopathy and failure. DESIGN We studied the effects of the AII1R antagonist eprosartan on MCP-1 expression, and on the recruitment of macrophages into the myocardium in a model of cardiac hypertrophy and morbidity/mortality. METHODS Stroke-prone spontaneously hypertensive rats fed a high-salt, high-fat diet (SFD) developed heart failure characterized by left ventricular (LV) hypertrophy/pathology and hypocontractility. These rats received either normal diet, SFD, or SFD with the daily administration of 30 mg/kg eprosartan for 28 weeks. LV function and wall thickness was assessed by echocardiography, MCP-1 expression was measured by TaqMan real-time polymerase chain reaction, enzyme-linked immunosorbent assay and immunohistochemistry, and macrophage infiltration into the LV was determined by microscopy. RESULTS Eprosartan reduced the rate of morbidity/mortality (P = 0.001), LV MCP-1 mRNA (P < 0.05) and protein expression (P < 0.01), and LV macrophage infiltration (P < 0.01), while preserving ventricular function (P < 0.05). Eprosartan also produced a moderate (16%; P < 0.05) decrease in blood pressure. CONCLUSIONS These data demonstrate that AII1R antagonism in an animal model of hypertensive heart disease reduces MCP-1 expression in the myocardium that results in reduced macrophage recruitment. These effects parallel the preservation of LV systolic function and the reduction in cardiac remodeling/disease progression and reduced morbidity/mortality. Suppression of MCP-1 expression might explain in part the beneficial effects of AII1R antagonism in this model.
Collapse
Affiliation(s)
- Thomas M Behr
- Medizinische Poliklinik, Department of Cardiology, University of Wuerzburg, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Maguire S, Strittmatter R, Chandra S, Barone FC. Stroke-prone rats exhibit prolonged behavioral deficits without increased brain injury: an indication of disrupted post-stroke brain recovery of function. Neurosci Lett 2004; 354:229-33. [PMID: 14700738 DOI: 10.1016/j.neulet.2003.09.079] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Stroke-prone rat strains exhibit an increased stroke risk and sensitivity, and reduced endogenous mechanisms of ischemic brain tolerance. This experiment provides a comparative, serial evaluation of neurological deficits and brain injury following middle cerebral artery occlusion/permanent focal stroke in this high-risk strain. Stroke-prone spontaneously hypertensive (SHR-SP), spontaneously hypertensive (SHR) and Wistar Kyoto (WKY) rats were evaluated over 28 days using magnetic resonance imaging (MRI), histopathology, and neurobehavioral testing. T2- and diffusion weighted-MRI was performed after 1, 10 and 28 days to measure the degree of stroke-induced brain injury. Normotensive WKY rats receiving the same stroke and other SHR-SP rats receiving sham surgery were used for control comparisons. Functional deficits were scored after 1, 4, 11, 18 and 28 days. The degree of brain infarction/injury was practically identical in hypertensive and stroke-prone rats. WKY rats exhibited significantly smaller infarcts (P<0.05), with neurological function recovering quickly to normal by day 11 in this strain. Functional deficits persisted longer in hypertensive rats, with function recovering to normal by day 18 (P<0.05). Functional deficits in SHR-SP rats persisted the longest, and were observed even after 28 days (P<0.05). This increased and prolonged neurologic dysfunction exhibited by SHR-SP compared to SHR rats, while exhibiting practically identical degrees of brain injury/infarction, reflects the increased stroke risk and sensitivity of this strain and suggests a reduced SHR-SP brain plasticity following injury. Therefore, the stroke-prone rat provides an enhanced and prolonged functional deficit model that can be used to elucidate those mechanisms/novel targets critical to longitudinal neurobehavioral recovery post-stroke.
Collapse
Affiliation(s)
- Sean Maguire
- Department of Laboratory Animal Science, GlaxoSmithKline, King of Prussia, PA 19406, USA
| | | | | | | |
Collapse
|
41
|
Wang X, Li X, Xu L, Zhan Y, Yaish-Ohad S, Erhardt JA, Barone FC, Feuerstein GZ. Up-Regulation of Secretory Leukocyte Protease Inhibitor (SLPI) in the Brain after Ischemic Stroke: Adenoviral Expression of SLPI Protects Brain from Ischemic Injury. Mol Pharmacol 2003; 64:833-40. [PMID: 14500739 DOI: 10.1124/mol.64.4.833] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Secretory leukocyte protease inhibitor (SLPI) is a 12-kDa secreted protein initially identified from epithelial cells as an inhibitor of leukocyte serine proteases. In the present study, we described the identification of SLPI expression in ischemic cortex by suppression subtractive hybridization strategy. Our full-length rat SLPI cDNA shares 81% and 63% amino acid sequence identity with its mouse and human homologs, respectively, and with several polymorphisms to previous reported rat sequences. Northern blot analysis confirmed that SLPI mRNA was significantly induced in the ischemic brain tissue at 12 h (5.1-fold increase over sham controls, n = 4, p < 0.05), peaked at 2 days (26.1-fold increase, p < 0.001), and sustained up to 5 days (5.1-fold increase, p < 0.05). SLPI was localized in neurons and astrocytes in the peri-infarct zone from 24 to 72 h after middle cerebral artery occlusion by means of immunohistochemical and confocal microscopy analysis. Administration of a recombinant adenovirus overexpressing SLPI (Adv/SLPI) into the cortical tissue resulted in up to 58.4% reduction in ischemic lesion over controls at the site of Adv/SLPI expression (p < 0.01, n = 8) and significantly improved functional outcome (p < 0.01). These data suggest that the ischemia-induced expression of SLPI might play a neuroprotective role in focal stroke, possibly because of rapid inhibition of activated proteases and its suppression in inflammatory response.
Collapse
Affiliation(s)
- Xinkang Wang
- Department of Thrombosis Research, Bristol Myers Squibb Company, 311 Pennington Rocky Hill Road, Pennington, NJ 08534, USA.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Legos JJ, Barone FC. Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. Curr Opin Investig Drugs 2003; 4:847-58. [PMID: 14619407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Given the few options that are currently available for patients following ischemic stroke, the search for novel therapeutic approaches becomes more critical. Pharmaceutical intervention strategies for the treatment of stroke include preventative (prophylactic or stroke pretreatment), neuroprotective (early acute post-stroke treatment) and regenerative (delayed post-stroke treatment for long-term benefit) therapeutic approaches. Experimental evidence has suggested that the majority of stroke patients have a slow evolution of brain injury that occurs over several hours. This 'evolving stroke' may ultimately be a realistic target for therapeutic intervention, with the goal of inhibiting the progression of detrimental changes that normally follow the acute ischemic event. Preventing or reducing this delayed cellular injury may improve neurological outcome and also facilitate brain recovery from injury. Significant impact on stroke can be expected as additional research is conducted on biological targets or processes important in facilitating the brain's regenerative capacity following cellular/tissue loss. This review provides updates on stroke prevention therapies (anticoagulant and antiplatelet), the advances in the development of pharmacological agents that target the acute phase of stroke (thrombolytics and neuroprotective drugs), and newly evolving approaches that may facilitate brain regeneration (i.e., neurobehavioral recovery) following brain damage.
Collapse
Affiliation(s)
- Jeffrey J Legos
- GlaxoSmithKline, PO Box 1539, 709 Swedeland Road, King of Prussia, PA 19406-0939, USA.
| | | |
Collapse
|
43
|
Purcell JE, Lenhard SC, White RF, Schaeffer T, Barone FC, Chandra S. Strain-dependent response to cerebral ischemic preconditioning: differences between spontaneously hypertensive and stroke prone spontaneously hypertensive rats. Neurosci Lett 2003; 339:151-5. [PMID: 12614917 DOI: 10.1016/s0304-3940(02)01476-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Ischemic preconditioning (PC) is a phenomenon whereby a brief exposure to ischemia renders a tissue more tolerant to a subsequent sustained ischemic insult. Animals of the Spontaneously Hypertensive (SHR) and the Spontaneously Hypertensive Stroke-Prone (SHR-SP) rat strains produce cerebral infarcts that are larger and more reproducible in size than infarcts of normotensive rats. This study compared the effects of PC in SHR and SHR-SP rats, under the hypothesis that PC may not be as effective in the SHR-SP, a strain genetically predisposed to stroke. There were two groups per strain, with between eight and ten animals each. The Precondition group (PC) had a 10 min occlusion of the middle cerebral artery on day -1. On the same day the Sham group (Sham) received sham surgery. On day 0, both groups underwent permanent occlusion of the middle cerebral artery. The ischemic lesion was measured on day 1 using T(2)-weighted magnetic resonance imaging. Percent hemispheric infarct was significantly reduced in SHR PC vs. SHR Sham, SHR-SP PC vs. SHR-SP Sham, and SHR PC vs. SHR-SP PC. Thus, rats of the SHR-SP strain respond to PC less markedly than SHR animals. Both models may now be used to elucidate the mechanisms underlying PC.
Collapse
Affiliation(s)
- Jeanette E Purcell
- Department of Laboratory Animal Science, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, USA.
| | | | | | | | | | | |
Collapse
|
44
|
McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, Aizenman E. Caspase 3 activation is essential for neuroprotection in preconditioning. Proc Natl Acad Sci U S A 2003; 100:715-20. [PMID: 12522260 PMCID: PMC141062 DOI: 10.1073/pnas.0232966100] [Citation(s) in RCA: 225] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Sublethal insults can induce tolerance to subsequent stressors in neurons. As cell death activators such as ROS generation and decreased ATP can initiate tolerance, we tested whether other cellular elements normally associated with neuronal injury could add to this process. In an in vivo model of ischemic tolerance, we were surprised to observe widespread caspase 3 cleavage, without cell death, in preconditioned tissue. To dissect the preconditioning pathways activating caspases, and the mechanisms by which these proteases are held in check, we developed an in vitro model of excitotoxic tolerance. In this model, antioxidants and caspase inhibitors blocked ischemia-induced protection against N-methyl-d-aspartate toxicity. Moreover, agents that blocked preconditioning also attenuated induction of HSP 70; transient overexpression of a constitutive form of this protein prevented HSP 70 up-regulation and blocked tolerance. We outline a neuroprotective pathway where events normally associated with apoptotic cell death are critical for cell survival.
Collapse
Affiliation(s)
- BethAnn McLaughlin
- Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
| | | | | | | | | | | | | |
Collapse
|
45
|
Legos JJ, McLaughlin B, Skaper SD, Strijbos PJLM, Parsons AA, Aizenman E, Herin GA, Barone FC, Erhardt JA. The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur J Pharmacol 2002; 447:37-42. [PMID: 12106800 DOI: 10.1016/s0014-2999(02)01890-3] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Inhibition of the p38 mitogen-activated protein kinase (MAP Kinase) pathway reduces acute ischemic injury in vivo, suggesting a direct role for this signaling pathway in a number of neurodegenerative processes. The present study was designed to evaluate further the role of p38 MAP Kinase in acute excitotoxic neuronal injury using the selective p38 inhibitor SB-239063 (trans-1-(4hydroxycyclohexyl)-4-(fluorophenyl)-5-(2-methoxy-pyrimidin-4-yl) imidazole). Unlike the widely used p38 inhibitor, SB-203580 (4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole), this second generation p38 inhibitor more selectively inhibits p38 MAP Kinase without affecting the activity of other MAP Kinase signaling pathways and provides a more accurate means to selectively assess the role of p38 in excitotoxicity that has not been previously possible. SB-239063 provided substantial protection against cell death induced by either oxygen glucose deprivation (OGD) or magnesium deprivation in cultured neurons. The ability of this compound to block excitotoxicity was not due to direct inhibition of N-methyl-D-aspartate (NMDA) receptor-mediated currents as SB-239063 did not alter NMDA electrophysiological responses. SB-239063 did not protect against a severe excitotoxic insult induced by 60-min exposure to NMDA. However, when tested against a less severe, brief (5 min) NMDA exposure, p38 inhibition provided substantial protection. These data demonstrate that inhibition of p38 MAP Kinase can confer neuroprotection in vitro against mild but not severe excitotoxic exposure, and suggests that other additional pathways/mechanism(s) may be involved in severe excitotoxic cell death.
Collapse
Affiliation(s)
- Jeffrey J Legos
- High Throughput Biology, Discovery Research, GlaxoSmithKline, PO Box 1539, Mail Code UW 2523, 709 Swedeland Road, 19406, King of Prussia, PA, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Toomey JR, Samanen J, Valocik RE, Koster PF, Barone FC, Willette RN. The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis. Curr Drug Targets Cardiovasc Haematol Disord 2002; 2:13-25. [PMID: 12769654 DOI: 10.2174/1568006023337772] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In patients with acute coronary syndromes, inhibition of platelet aggregation with parenteral alpha(IIb)/beta(III) antagonists has proven effective at preventing nonfatal myocardial infarction and repeat percutaneous coronary interventions. Paradoxically, the efficacy observed for acute indications and parenteral agents has not extended to oral agents and chronic prevention of secondary thrombotic events, despite robust antithrombotic properties in preclinical thrombosis models. This report documents the preclinical data of Lotrafiban, an oral alpha(IIb)/beta(III) antagonist that recently failed in a phase III clinical trial (BRAVO) for the prevention of secondary thrombosis. Lotrafiban was characterized in a dog circumflex artery electrical injury model, and a cyclic flow reduction model ("Folts"). The data demonstrate that both oral (1.0-50.0 mg/kg) and intravenous (0.1-0.8ug/kg/min) administration of lotrafiban produced dose-related inhibition (45%-95%) of ex vivo platelet aggregation. In the electrical injury model, the dose-related inhibition correlated with a significant reduction in the frequency of coronary occlusion, size of the developing thrombus, and the extent of left ventricular ischemic damage. Effects on blood flow and bleeding time were also dose related. The combination of low dose lotrafiban (0.1ug/kg/min) and aspirin (5.0 mg/kg) generated additive antithrombotic effects, approximating the antithrombotic efficacy of a 2-4 fold higher dose of lotrafiban while only modestly prolonging the bleeding time. For purposes of comparison, the ADP receptor antagonist clopidogrel was also assessed in the electrical injury model. Clopidogrel (5.0-10.0 mg/kg, iv.) significantly reduced the resulting left ventricular infarct areas, but lacked the overall efficacy of lotrafiban. In the "Folts" model, lotrafiban inhibited cyclic blood flow reductions (CFR's) by 100% in animals insensitive to the antithrombotic effects of aspirin. Overall, the preclinical data demonstrated that alpha(IIb)/beta(III) antagonism with lotrafiban was a well tolerated and effective strategy for attenuating acute arterial thrombosis. The lack of a correlation between these preclinical data and the outcome of the clinical trial BRAVO are unexplained. However, the combined evidence suggests that these acute canine thrombosis studies may not completely capture the pathology reflected in chronic human atherothrombotic disease.
Collapse
Affiliation(s)
- John R Toomey
- Department of Cardiovascular Pharmacology, GlaxoSmithKline, 709 Swedeland Road, PO Box 1539, Mail code UW 2510, King of Prussia, PA 19406, USA.
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
Given the few options currently available for patients following ischaemic stroke, the recent disappointing failures of several large-scale Phase III clinical trials has made the search for novel therapeutic approaches even more critical. Experimental evidence has suggested that the majority of stroke patients have a slow evolution of brain injury which can occur over several hours. Progressive microcirculatory failure following the initial onset of ischaemia may contribute to the expansion of brain injury. Included among the pathophysiological changes that are speculated to occur as a secondary response to the initial ischaemia are free radical production, excitotoxicity (for example, glutamate) disruption of ionic homeostasis (for example, sodium and calcium influx), enzymatic changes, stimulation of the inflammatory process, endothelin release, activation of platelets and leukocytes, delayed coagulation and endothelial dysfunction. All of these pathophysiological reactions could contribute to an increase in local vascular resistance and therefore cause progressive hypoperfusion of the brain following the onset of stroke. The scope of this review will focus on recent clinical failures in addition to agents currently in clinical development, comparing vascular targets to the common neuroprotective strategies.
Collapse
Affiliation(s)
- Jeffrey J Legos
- High Throughput Biology, Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA.
| | | | | |
Collapse
|
48
|
Abrahamsen CT, Barone FC, Campbell WG, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, Brooks DP. The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. J Pharmacol Exp Ther 2002; 301:21-8. [PMID: 11907153 DOI: 10.1124/jpet.301.1.21] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The effects of the angiotensin type 1 (AT(1)) receptor antagonist, eprosartan, were studied in a model of severe, chronic hypertension. Treatment of male spontaneously hypertensive stroke prone rats (SHR-SP) fed a high-fat, high-salt diet with eprosartan (60 mg/kg/day i.p.) for 12 weeks resulted in a lowering of blood pressure (250 +/- 9 versus 284 +/- 8 mm Hg), renal expression of transforming growth factor-beta mRNA (1.5 +/- 0.2 versus 5.4 +/- 1.4) and the matrix components: plasminogen activator inhibitor-1 (5.2 +/- 1.4 versus 31.4 +/- 10.7), fibronectin (2.2 +/- 0.6 versus 8.2 +/- 2.2), collagen I-alpha 1 (5.6 +/- 2.0 versus 23.8 +/- 7.3), and collagen III (2.7 +/- 0.9 versus 7.6 +/- 2.1). Data were corrected for rpL32 mRNA expression and expressed relative to Wistar Kyoto (WKY) rats [=1.0]. Expression of fibronectin protein was also lowered by eprosartan (0.8 +/- 0.1 versus 1.9 +/- 0.5), relative to WKY rats. Eprosartan provided significant renoprotection to SHR-SP rats as measured by decreased proteinuria (22 +/- 2 versus 127 +/- 13 mg/day) and histological evidence of active renal damage (5 +/- 2 versus 195 +/- 6) and renal fibrosis (5.9 +/- 0.7 versus 16.4 +/- 1.9) in vehicle- versus eprosartan-treated rats, respectively. Our results demonstrated that AT(1) receptor blockade with eprosartan can reduce blood pressure and preserve renal structure and function in this model of severe, chronic hypertension. These effects were accompanied by a decreased renal expression of transforming growth factor-beta1, plasminogen activator inhibitor-1, and several other extracellular matrix proteins compared with vehicle-treated SHR-SP.
Collapse
Affiliation(s)
- Christian T Abrahamsen
- Department of Renal Pharmacology, GlaxoSmithKline, King of Prussia, Pennsylvania 19406-0939, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, Barone FC, Ma XL. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 2002; 53:414-22. [PMID: 11827692 DOI: 10.1016/s0008-6363(01)00488-6] [Citation(s) in RCA: 100] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND In vitro evidence suggests that the p38 mitogen-activated protein kinase (p38 MAPK) plays a crucial role in PMN activation and inflammatory cytokine production. However, the effect of p38 MAPK on myocardial reperfusion injury, a pathologic condition involving a typical inflammatory response, has not been fully examined. In the present study, we investigated the effect of SB 239063, a specific p38 MAPK inhibitor, on myocardial injury in a murine ischemia/reperfusion (I/R) model and elucidated the mechanism by which p38 MAPK inhibitor may exert its protective effect against I/R injury. METHODS AND RESULTS I/R resulted in a significant myocardial injury (myocardial infarct 45 +/- 2.9%) and marked PMN accumulation (myeloperoxidase activity 1.03 +/- 0.16 U/100 g tissue). Administration of SB 239063 significantly inhibited the myocardial inflammatory response as evidenced by reduced PMN accumulation in I/R myocardial tissue (0.62 +/- 0.008 U/100 g tissue, P<0.01 vs. vehicle), and markedly attenuated myocardial reperfusion injury (myocardial infarct size: 28 +/- 2.4%, P<0.01 vs. vehicle). Moreover, treatment with SB 239063 significantly attenuated I/R-induced P-selectin and ICAM-1 upregulation (13.8 +/- 2.7 vs. 23.9 +/- 3.1%, and 29.4 +/- 1.6 vs. 56.3 +/- 4.8%, respectively P<0.01). In addition, pre-treatment with R15.7, a monoclonal antibody against CD 18 adhesion molecule on PMN surface that virtually abolished PMN accumulation in ischemic-reperfused myocardial tissue, significantly, but not completely, blocked the cardioprotection exerted by SB 239063. CONCLUSION These results demonstrated for the first time that p38 MAPK activation plays a significant role in adhesion molecule upregulation on ischemia-reperfused endothelial cells and is an important signaling step in the pathogenesis of PMN-mediated tissue injury.
Collapse
Affiliation(s)
- Feng Gao
- Division of Emergency Medicine, Jefferson Medical College, Thomas Jefferson University, 1020 Sansom Street, Philadelphia, PA 19107-5004, USA
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC. Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. Stroke 2002; 33:578-85. [PMID: 11823673 DOI: 10.1161/hs0202.102950] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE Although used clinically to prevent stroke, there are few examples of anticoagulant investigations in the treatment of acute thromboembolic stroke in animal models. The treatment of thromboembolic stroke in experimental models has been investigated almost exclusively around the use of tissue plasminogen activator (tPA). In this study, using a rat thromboembolic stroke model, we investigated the use of an inhibitory anti-factor IX(a) monoclonal antibody (SB 249417) for the treatment of thromboembolic stroke and compared its efficacy to that of tPA. METHODS Stroke was initiated by delivering 6 clots into the internal carotid artery. After 2, 4, or 6 hours, rats received either intravenous vehicle, 10.0 mg/kg tPA, or 1.0, 2.0, or 3.0 mg/kg SB 249417. At 24 hours after stroke, infarct volumes and neurological deficits were assessed. RESULTS Treatment with tPA 2, 4, or 6 hours after stroke reduced infarct volumes by 35% (P=NS), 45%, and 39%, respectively. tPA treatment did not improve neurological deficits at any time point. Treatment with SB 249417 (3.0 mg/kg) 2, 4, or 6 hours after stroke reduced infarct volumes by 44%, 50%, and 13% (P=NS), respectively. Neurological deficits were reduced by 49%, 42%, and 13% (P=NS), respectively. Neither mortality nor hemorrhage was affected by either treatment. CONCLUSIONS The data indicate that the inhibition of factor IX(a) within 4 hours of thromboembolic stroke produced a more favorable outcome than tPA. When treatment was initiated 6 hours after stroke, the benefits of factor IX(a) inhibition were lost, whereas tPA continued to suppress lesion development, albeit without a corresponding improvement in functional deficits. This study suggests that cerebral ischemia and the resultant perfusion deficit are exacerbated by the activation of blood coagulation and that anticoagulants like SB 249417 may find utility in the treatment of ischemic stroke.
Collapse
Affiliation(s)
- John R Toomey
- Department of Cardiovascular Pharmacology, GlaxoSmithKline, King of Prussia, Pa 19406, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|